-
New Two-Year Data Supports Long-Term Management of Classic Congenital Adrenal Hyperplasia with CRENESSITY®
NASDAQ: $NBIX For individuals living with classic congenital adrenal hyperplasia (CAH), the standard of care has long presented a difficult dilemma. While patients require glucocorticoids (GCs) to survive, the historical reliance on supraphysiologic doses—doses higher than what the body naturally produces—has carried a heavy burden of long-term health risks, including metabolic complications, bone density loss,…